ArticleCellular signalling2021

The SGLT2 inhibitor Empagliflozin attenuates interleukin-17A-induced human aortic smooth muscle cell proliferation and migration by targeting TRAF3IP2/ROS/NLRP3/Caspase-1-dependent IL-1β and IL-18 secretion.

Sergiy Sukhanov et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.